These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 11544577)

  • 1. Use of markers of bone turnover for monitoring bone metastases and the response to therapy.
    Lipton A; Costa L; Ali S; Demers L
    Semin Oncol; 2001 Aug; 28(4 Suppl 11):54-9. PubMed ID: 11544577
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Markers of bone turnover in bone metastases.
    Fontana A; Delmas PD
    Cancer; 2000 Jun; 88(12 Suppl):2952-60. PubMed ID: 10898339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biochemical markers of bone turnover in breast cancer patients with bone metastases: a preliminary report.
    Shimozuma K; Sonoo H; Fukunaga M; Ichihara K; Aoyama T; Tanaka K
    Jpn J Clin Oncol; 1999 Jan; 29(1):16-22. PubMed ID: 10073146
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biochemical markers and skeletal metastases.
    Demers LM; Costa L; Lipton A
    Cancer; 2000 Jun; 88(12 Suppl):2919-26. PubMed ID: 10898335
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biochemical markers of bone turnover and clinical outcomes in men with prostate cancer.
    Saad F; Eastham JA; Smith MR
    Urol Oncol; 2012; 30(4):369-78. PubMed ID: 21163673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of markers of bone remodeling in multiple myeloma.
    Terpos E; Politou M; Rahemtulla A
    Blood Rev; 2005 May; 19(3):125-42. PubMed ID: 15748961
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biochemical markers of bone turnover in patients with metastatic bone disease.
    Demers LM; Costa L; Chinchilli VM; Gaydos L; Curley E; Lipton A
    Clin Chem; 1995 Oct; 41(10):1489-94. PubMed ID: 7586522
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The clinical use of bone resorption markers in patients with malignant bone disease.
    Coleman RE
    Cancer; 2002 May; 94(10):2521-33. PubMed ID: 12173317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical utility of biochemical marker of bone remodelling in patients with bone metastases of solid tumors.
    Seregni E; Martinetti A; Ferrari L; Bombardieri E
    Q J Nucl Med; 2001 Mar; 45(1):7-17. PubMed ID: 11456378
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The biochemical markers of bone remodeling in cancer patients with skeletal involvement].
    Liubimova NV; Bronnikov IIu; Robins SP; Trapeznikova MF; Kushlinskiĭ NE
    Vopr Onkol; 2000; 46(3):290-7. PubMed ID: 10976274
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Collagen cross-link metabolites in urine as markers of bone metastases in prostatic carcinoma.
    Miyamoto KK; McSherry SA; Robins SP; Besterman JM; Mohler JL
    J Urol; 1994 Apr; 151(4):909-13. PubMed ID: 7510346
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The amino-terminal propeptide (PINP) of type I collagen is a clinically valid indicator of bone turnover and extent of metastatic spread in osseous metastatic breast cancer.
    Pollmann D; Siepmann S; Geppert R; Wernecke KD; Possinger K; Lüftner D
    Anticancer Res; 2007; 27(4A):1853-62. PubMed ID: 17649784
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biochemical markers and skeletal metastases.
    Demers LM; Costa L; Lipton A
    Clin Orthop Relat Res; 2003 Oct; (415 Suppl):S138-47. PubMed ID: 14600604
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biochemical markers of bone turnover in patients with spinal metastases after resistance training under radiotherapy--a randomized trial.
    Rief H; Omlor G; Akbar M; Bruckner T; Rieken S; Förster R; Schlampp I; Welzel T; Bostel T; Roth HJ; Debus J
    BMC Cancer; 2016 Mar; 16():231. PubMed ID: 26983672
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bone markers in the management of patients with skeletal metastases.
    Demers LM
    Cancer; 2003 Feb; 97(3 Suppl):874-9. PubMed ID: 12548589
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of bone scintigraphy with bone markers in the diagnosis of bone metastasis in lung carcinoma patients.
    Ebert W; Muley T; Herb KP; Schmidt-Gayk H
    Anticancer Res; 2004; 24(5B):3193-201. PubMed ID: 15510610
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biochemical markers of bone turnover in the clinical development of drugs for osteoporosis and metastatic bone disease: potential uses and pitfalls.
    Cremers S; Garnero P
    Drugs; 2006; 66(16):2031-58. PubMed ID: 17112299
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Can bone markers guide more effective treatment of bone metastases from breast cancer?
    Clemons M; Cole DE; Gainford MC
    Breast Cancer Res Treat; 2006 May; 97(1):81-90. PubMed ID: 16319976
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of biochemical markers of bone resorption in patients with metabolic and malignant bone diseases.
    Withold W; Friedrich W; Reinauer H
    Ann Clin Biochem; 1996 Sep; 33 ( Pt 5)():421-7. PubMed ID: 8888974
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of molecular markers of bone turnover in the management of patients with metastatic bone disease.
    Seibel MJ
    Clin Endocrinol (Oxf); 2008 Jun; 68(6):839-49. PubMed ID: 17980010
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.